These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 30277471)

  • 21. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
    Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
    Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.
    Palma M; Gentilcore G; Heimersson K; Mozaffari F; Näsman-Glaser B; Young E; Rosenquist R; Hansson L; Österborg A; Mellstedt H
    Haematologica; 2017 Mar; 102(3):562-572. PubMed ID: 27927767
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
    Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
    Front Immunol; 2020; 11():590072. PubMed ID: 33329575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.
    Qorraj M; Bruns H; Böttcher M; Weigand L; Saul D; Mackensen A; Jitschin R; Mougiakakos D
    Leukemia; 2017 Feb; 31(2):470-478. PubMed ID: 27479178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
    Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
    J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and functional characterization of exhausted CD8
    Taghiloo S; Allahmoradi E; Tehrani M; Hossein-Nataj H; Shekarriz R; Janbabaei G; Abediankenari S; Asgarian-Omran H
    Eur J Haematol; 2017 Jun; 98(6):622-631. PubMed ID: 28306177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD4+ T Cells are Exhausted and Show Functional Defects in Chronic Lymphocytic Leukemia.
    Allahmoradi E; Taghiloo S; Tehrani M; Hossein-Nattaj H; Janbabaei G; Shekarriz R; Asgarian-Omran H
    Iran J Immunol; 2017 Dec; 14(4):257-269. PubMed ID: 29276179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
    Wang Y; Wu L; Tian C; Zhang Y
    Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD84 cell surface signaling molecule: An emerging biomarker and target for cancer and autoimmune disorders.
    Cuenca M; Sintes J; Lányi Á; Engel P
    Clin Immunol; 2019 Jul; 204():43-49. PubMed ID: 30522694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological Study of PD-1/PD-L1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with Emphasis on Large B-Cell Richter Transformation.
    Masoud R; Eladl AE; El-Ashwah S; Abbas A; Kandil W
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4243-4252. PubMed ID: 38156860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TBET-expressing Th1 CD4
    Roessner PM; Hanna BS; Öztürk S; Schulz R; Llaó Cid L; Yazdanparast H; Scheffold A; Colomer D; Stilgenbauer S; Lichter P; Seiffert M
    Br J Haematol; 2020 Apr; 189(1):133-145. PubMed ID: 31724172
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN-γ by a T-bet-dependent mechanism.
    Bürgler S; Gimeno A; Parente-Ribes A; Wang D; Os A; Devereux S; Jebsen P; Bogen B; Tjønnfjord GE; Munthe LA
    J Immunol; 2015 Jan; 194(2):827-35. PubMed ID: 25505279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 35. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
    Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
    Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic lymphocytic leukemia.
    Cox MJ; Lucien F; Sakemura R; Boysen JC; Kim Y; Horvei P; Manriquez Roman C; Hansen MJ; Tapper EE; Siegler EL; Forsman C; Crotts SB; Schick KJ; Hefazi M; Ruff MW; Can I; Adada M; Bezerra E; Kankeu Fonkoua LA; Nevala WK; Braggio E; Ding W; Parikh SA; Kay NE; Kenderian SS
    Mol Ther; 2021 Apr; 29(4):1529-1540. PubMed ID: 33388419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.
    Banerjee P; Zhang R; Ivan C; Galletti G; Clise-Dwyer K; Barbaglio F; Scarfò L; Aracil M; Klein C; Wierda W; Plunkett W; Caligaris-Cappio F; Gandhi V; Keating MJ; Bertilaccio MTS
    Cancer Immunol Res; 2019 Dec; 7(12):2036-2051. PubMed ID: 31530560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation.
    Hartley GP; Chow L; Ammons DT; Wheat WH; Dow SW
    Cancer Immunol Res; 2018 Oct; 6(10):1260-1273. PubMed ID: 30012633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1 /PD-L1 checkpoint in hematological malignancies.
    Annibali O; Crescenzi A; Tomarchio V; Pagano A; Bianchi A; Grifoni A; Avvisati G
    Leuk Res; 2018 Apr; 67():45-55. PubMed ID: 29428449
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
    Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
    Front Immunol; 2020; 11():612244. PubMed ID: 33552073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.